Jump to content

PF-05089771

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Yobot (talk | contribs) at 17:05, 9 March 2016 (WP:CHECKWIKI error fixes/ ISSN syntax fixes using AWB (11967)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

PF-05089771 is a selective, small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker under development by Pfizer as a novel analgesic.[1][2] As of June 2014, it has completed phase II clinical trials for wisdom tooth removal and primary erythromelalgia.[3]

See also

References

  1. ^ McMahon, Stephen; Koltzenburg, Martin; Tracey, Irene; Turk, Dennis C. (1 March 2013). Wall & Melzack's Textbook of Pain: Expert Consult - Online. Elsevier Health Sciences. p. 508. ISBN 0-7020-5374-0.
  2. ^ Martz, Lauren (2014). "Nav-i-gating antibodies for pain". Science-Business eXchange. 7 (23). doi:10.1038/scibx.2014.662. ISSN 1945-3477.
  3. ^ Bagal, Sharan K.; Chapman, Mark L.; Marron, Brian E.; Prime, Rebecca; Ian Storer, R.; Swain, Nigel A. (2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. ISSN 0960-894X. PMID 25060923.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=PF-05089771&oldid=709194456"